Dr Reddy's completes acquisition of Haleon's NRT portfolio
Dr. Reddy's Laboratories announced that its subsidiary in Switzerland has successfully acquired the global portfolio of consumer healthcare products in the nicotine replacement therapy (NRT) category owned by Haleon plc, excluding the United States. Dr Reddy's Laboratories SA finalized the acquisition by purchasing shares in Northstar Switzerland SARL, a Haleon group firm.
According to the statement, Northstar Switzerland, North Star OpCo, and North Star Sweden AB (Sweden), acquired as part of the deal, are now wholly-owned step-down subsidiaries of the business as of September 30, 2024. The portfolio that was acquired includes local market-leading brand names of the product as well as Nicotinell, a worldwide leader in the NRT category with a presence in over 30 countries in Europe, Asia, Latin America, and Japan.